Mimedx Group Stock Today
| MDXG Stock | USD 9.16 0.28 2.97% |
Performance13 of 100
| Odds Of DistressLess than 2
|
MiMedx is trading at 9.16 as of the 17th of December 2024. This is a 2.97 percent decrease since the beginning of the trading day. The stock's lowest day price was 9.07. MiMedx has a very small chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 17th of November 2024 and ending today, the 17th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of August 2007 | Category Healthcare | Classification Health Care |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. The company has 146.95 M outstanding shares of which 3.42 M shares are now shorted by private and institutional investors with about 3.07 trading days to cover. More on MiMedx Group
Moving together with MiMedx Stock
| 0.82 | DYAI | Dyadic International | PairCorr |
| 0.77 | ESPR | Esperion Therapeutics | PairCorr |
| 0.81 | BMY | Bristol Myers Squibb | PairCorr |
Moving against MiMedx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
MiMedx Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Joseph Capper | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMiMedx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MiMedx's financial leverage. It provides some insight into what part of MiMedx's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MiMedx Group (MDXG) is traded on NASDAQ Exchange in USA. It is located in 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062 and employs 895 people. MiMedx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.39 B. MiMedx Group conducts business under Biotechnology sector and is part of Health Care industry. The entity has 146.95 M outstanding shares of which 3.42 M shares are now shorted by private and institutional investors with about 3.07 trading days to cover.
MiMedx Group currently holds about 72.5 M in cash with 26.77 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64.
Check MiMedx Probability Of Bankruptcy
Ownership AllocationMiMedx Group maintains a total of 146.95 Million outstanding shares. Over half of MiMedx's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MiMedx Ownership Details
MiMedx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.2 M | |
| Northern Trust Corp | 2024-09-30 | 1.1 M | |
| Royal Bank Of Canada | 2024-09-30 | 1.1 M | |
| Harbor Capital Advisors Inc | 2024-09-30 | 1 M | |
| Royce & Associates, Lp | 2024-09-30 | 972.9 K | |
| Federated Hermes Inc | 2024-09-30 | 906.8 K | |
| Qube Research & Technologies | 2024-09-30 | 894.7 K | |
| Richmond Brothers Inc | 2024-09-30 | 782.7 K | |
| Essex Woodlands Health Ventures | 2024-09-30 | 28.2 M | |
| Blackrock Inc | 2024-06-30 | 9.3 M |
MiMedx Historical Income Statement
MiMedx Stock Against Markets
MiMedx Corporate Management
| Matthew Notarianni | Head Relations | Profile | |
| Todd Newton | Interim Director | Profile | |
| William Phelan | VP Officer | Profile | |
| Kim Moller | Chief Officer | Profile | |
| William IV | General Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.59 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.